PTK2 and neoplasm: In PDX Model 2, which was derived from a female patient with FAK6,7 and mutant TP53 and Rb1, PF562271 strongly inhibited tumor growth (Fig. 7j, k), reduced tumor weight (Fig. 7l), and suppressed the expression of p-FAK and Ki67 (Fig. 7m–o).